News in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...

Basel: This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to ...

A drug commonly used to treat breast cancer might be able to help people living with hereditary hemorrhagic telangiectasia ...

“We look forward to presenting updated data from our ongoing Phase 2 clinical study of palazestrant in combination with ribociclib in frontline metastatic breast cancer patients at SABCS in December.

The ribociclib population is more broad ... HER2-negative [HER2–] metastatic breast cancer. They not only improve the PFS, but also improve the overall survival. It's really hard to see any ...

Common hormone therapies include: HER2-Positive Breast Cancer: Drugs like trastuzumab (Herceptin) and pertuzumab (Perjeta) target the HER2 protein, which promotes cancer cell growth. CDK4/6 Inhibitors ...

The women had early stage breast cancer that was HR-positive and HER2-negative. When compared to chemotherapy, the ribociclib and letrozole were found to be just as effective and better tolerated.

Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah, discusses new treatments for HR+/HER2- breast cancer and immunotherapy challenges, ...

Chen cites Ribociclib, a drug used for many years for those with metastatic breast cancer. Recent studies show that it also significantly improves survival among patients with HR-positive ...

Ribociclib, in combination with the aromatase inhibitor letrozole, improves survival in post-menopausal women with hormone receptor-positive metastatic breast cancer. Breast cancer is a cancer ...

This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to recommend ribociclib (Kisqali) as a Category 1 preferred CDK4/6 inhibitor (CDK4/6i) ...

This month, the NCCN Clinical Practice Guidelines in Oncology, NCCN Guidelines, for breast cancer were updated to recommend ribociclib as a Category 1 preferred CDK4/6 inhibitor adjuvant therapy ...